Earlier diagnosis and a more individualized choice of treatment options has the potential to greatly improve the outcome of life-threatening diseases. DNA methylation has proven to be a rich source of biomarkers for diagnosis, prognosis and drug response prediction in cancer and other diseases. Epigenomics AG makes use of DNA methylation biomarkers to develop in vitro diagnostic test products. The product pipeline comprises screening tests for the early detection of cancer in body fluids and molecular pathology tests on routinely available tissue samples for cancer prognosis. In collaborations with pharmaceutical and biotechnology companies, Epigenomics provides access to its broad range of technologies for the support of drug development and commercialization by patient stratification and drug response prediction.